FDA Issues Draft Guidance For IDEs For Neurological Devices

The U.S. Food and Drug Administration (FDA) released a draft guidance for sponsors who wish to submit an investigational device exemption (IDE) to conduct trials for devices intended to slow, stop, or reverse the effects of neurological diseases, including Alzheimer's disease, Parkinson's disease, or primary dystonia.
Source: Medical Design Online News - Category: Medical Equipment Source Type: news